Breast cancer Chemotherapy Interleukin-6 Tumor necrosis factor-alpha Memory Hippocampus MRI a b s t r a c t Many survivors of breast cancer show significant cognitive impairments, including memory deficits. Inflammation induced by chemotherapy may contribute to hippocampal changes that underlie these deficits. In this cross-sectional study, we measured bilateral hippocampal volumes from high-resolution magnetic resonance images in 42 chemotherapy-treated breast cancer survivors and 35 healthy female controls. Patients with breast cancer were, on average, 4.8 ± 3.4 years off-therapy. In a subset of these participants (20 breast cancer, 23 controls), we quantified serum cytokine levels. Left hippocampal volumes and memory performance were significantly reduced and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFa) concentrations were significantly elevated in the breast cancer group compared to controls. In the breast cancer group, lower left hippocampal volume was associated with higher levels of TNFa and lower levels of IL-6 with a significant interaction between these two cytokines suggesting a potential modulatory effect of IL-6 on TNFa. Verbal memory performance was associated with cytokine levels and left hippocampal volume in both groups. These findings provide evidence of altered hippocampal volume and verbal memory difficulties following breast cancer chemotherapy that may be mediated by TNFa and IL-6.
Introduction
Cognitive impairments are a common late effect of breast cancer and its treatments affecting as many as 75% of survivors (Janelsins et al., 2011; Wefel et al., 2011) . Memory impairments are among the most consistently observed difficulties following breast cancer treatment (Jansen et al., 2005; Correa and Ahles, 2008; Janelsins et al., 2011; Wefel et al., 2011) and may involve abnormality of the hippocampus, a region critical for memory function (Squire et al., 2010; Squire and Wixted, 2011) . Animal models suggest that chemotherapy-related and/or pro-inflammatory cytokine neurotoxicity may specifically cause damage to the hippocampus (Tangpong et al., 2006; Winocur et al., 2006; Fardell et al., 2010; Joshi et al., 2010; Aluise et al., 2011; Seigers and Fardell, 2011) .
Although chemotherapeutic agents typically have restricted direct access to brain tissue due to the blood-brain barrier (BBB), disease states such as cancer, radiation treatment, genetic variations and other factors may make the BBB more permeable to chemotherapy, or may induce alterations in endothelial cells that trigger microenvironment changes within the brain (Ahles and Saykin, 2007; Deeken and Loscher, 2007; Wefel et al., 2008) . The hippocampus is unique in that it is one of the only brain regions of continued neural stem cell proliferation throughout the lifespan (Eriksson et al., 1998; Gage, 2000) . Neural stem cell proliferation is very tightly regulated and highly sensitive to microenvironment changes. Although chemotherapeutic agents such as doxorubicin (one of the most common breast cancer treatments) are not known to readily cross the BBB, these drugs are associated with reduced hippocampal neurogenesis (Janelsins et al., 2010) . Specifically, many chemotherapeutic agents cause neural progenitor cells to lose their capacity for self-renewal even after an initial dose, particularly in the hippocampus (Dietrich et al., 2006 (Dietrich et al., , 2010 Winocur et al., 2006; Seigers et al., 2008 Seigers et al., , 2009 ). Repetitive dosing, as most patients with breast cancer experience, causes persistent suppression of cell division in the hippocampus (Dietrich et al., 2006; Dietrich, 2010; Hyrien et al., 2010) . Both dividing and non-dividing neural and glial cells are significantly vulnerable to chemotherapies (Dietrich et al., 2006 (Dietrich et al., , 2010 Winocur et al., 2006; Seigers 
